Abstract
Objective:
In this study we have examined for the first time the signal transduction mechanisms involved in the generation of pressure-dependent myogenic tone in human small resistance arteries from the subcutaneous vascular bed.
Methods:
Myogenic responses and the subcellular mechanisms involved in the generation of this response were studied on a pressure myograph.
Results and conclusion:
Human subcutaneous resistance arteries constricted 14.1+/-1.1% in response to an increases in intraluminal pressure from 40 to 80 mmHg and a further 3.5+/-1.7% in response to the 80-120-mmHg pressure step. Ca(2+) depletion or nifedipine abolished this response, whereas BAY K 8644 increased this response to 20.6+/-2.1% (P<0.05, response vs. control). The phospholipase C inhibitor U-73122 reduced the myogenic response to 2.5+/-1.0% at 80 mmHg (P<0.01, response vs. control) and abolished it at 120 mmHg. Diacylglycerol lipase inhibition with RHC-80267 abolished all myogenic responses to pressure. The protein kinase C (PKC) activator phorbol 12,13-dibutyrate increased the maximal myogenic response to 20.9+/-1.8% (P<0.05, response vs. control), whereas the PKC inhibitor calphostin C abolished myogenic responses. These data show that the generation of pressure-dependent myogenic tone in human subcutaneous arteries is dependent on Ca(2+) influx via voltage operated Ca(2+) channels (VOCCs) and a concomitant requirement for the activation of phospholipase C (PLC), diacylglycerol, and PKC.
MeSH terms
-
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / pharmacology
-
Aged
-
Analysis of Variance
-
Arteries
-
Caffeine / pharmacology
-
Calcium / metabolism*
-
Calcium Channel Blockers / pharmacology
-
Calcium Channels / drug effects
-
Calcium-Transporting ATPases / antagonists & inhibitors
-
Cyclohexanones / pharmacology
-
Enzyme Inhibitors
-
Estrenes / pharmacology
-
Female
-
Humans
-
In Vitro Techniques
-
Indoles / pharmacology
-
Lipoprotein Lipase / antagonists & inhibitors
-
Male
-
Middle Aged
-
Muscle, Smooth, Vascular / physiology*
-
Naphthalenes / pharmacology
-
Nifedipine / pharmacology
-
Phorbol 12,13-Dibutyrate / pharmacology
-
Protein Kinase C / antagonists & inhibitors
-
Pyrrolidinones / pharmacology
-
Ryanodine / pharmacology
-
Ryanodine Receptor Calcium Release Channel / drug effects
-
Signal Transduction / physiology*
-
Type C Phospholipases / antagonists & inhibitors
-
Vascular Resistance / physiology*
Substances
-
Calcium Channel Blockers
-
Calcium Channels
-
Cyclohexanones
-
Enzyme Inhibitors
-
Estrenes
-
Indoles
-
Naphthalenes
-
Pyrrolidinones
-
Ryanodine Receptor Calcium Release Channel
-
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
-
Ryanodine
-
Phorbol 12,13-Dibutyrate
-
Caffeine
-
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
-
1,6-bis(cyclohexyloximinocarbonyl)hexane
-
Protein Kinase C
-
Lipoprotein Lipase
-
Type C Phospholipases
-
Calcium-Transporting ATPases
-
calphostin C
-
Nifedipine
-
Calcium
-
cyclopiazonic acid